Cinemark Holdings, Inc. Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025, for Cinemark Holdings, Inc. ("Holdings") and its primary operating subsidiary, Cinemark USA, Inc. ("CUSA"). The company operates in the theatrical exhibition industry with 497 theaters and 5,644 screens across the U.S. and 13 Latin American countries. The filing is a combined report for both entities, with CUSA comprising nearly 100% of Holdings' operating revenue and expenses.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $540.7 million | $579.2 million |
| Operating Income (Loss) | ($19.2) million | $17.6 million |
| Net Income (Loss) | ($38.6) million | $25.3 million |
| Diluted EPS | ($0.32) | $0.19 |
| Adjusted EBITDA | $36.4 million | $70.7 million |
| Cash and Equivalents | $699.4 million | $788.6 million |
| Total Debt (Carrying Value) | $2,362.1 million | $2,363.7 million |
| Free Cash Flow (Operating) | ($119.1) million | ($22.7) million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 6.6% year-over-year. U.S. admissions revenue fell 10.4% due to fewer tentpole releases, while international revenue remained relatively flat (1.1% increase) despite currency headwinds.
- Profitability Shift: The company reported an operating loss of $19.2 million compared to operating income of $17.6 million in Q1 2024. This was driven by lower revenue and increased operating costs, including a 3.9% rise in salaries and wages and a 5.3% increase in utilities and other expenses.
- Segment Performance: U.S. Adjusted EBITDA dropped significantly to $20.0 million from $49.1 million in the prior year. International Adjusted EBITDA was $16.4 million, down from $21.6 million.
- Asset Sales: A gain of $4.1 million was recorded on the disposal of assets, primarily from the sale of a land parcel and an owned theater property, partially offsetting operating losses.
Guidance, Outlook, and Risks
- Share Repurchases: On March 6, 2025, the Board authorized a $200 million share repurchase program. The company completed the full $200 million repurchase by March 27, 2025.
- Dividends: The Board reinstated the quarterly cash dividend at $0.08 per share, with the first payment made on March 19, 2025.
- Debt Maturity: The $460 million 4.50% Convertible Senior Notes mature in August 2025. The notes are currently convertible as the stock price exceeded the trigger price. Management intends to settle the principal with cash and the remainder with shares.
- Capital Expenditures: Total CapEx was $22.1 million. The company has signed commitments for $46.4 million in future theater development and expansions.
- Risks: Key risks include the volume and performance of new film content, inflationary pressures on labor and concession costs, foreign currency exchange fluctuations (particularly in Argentina), and ongoing legal proceedings including class actions regarding labor practices and product labeling.
Investor Verification Checklist
- Convertible Note Settlement: Verify the final settlement method (cash vs. shares) for the $460 million Convertible Senior Notes maturing in August 2025.
- U.S. Box Office Recovery: Monitor upcoming film release schedules to assess the sustainability of the 12.7% decline in U.S. attendance.
- Cost Inflation: Track wage inflation and concession supply costs, which increased as a percentage of revenue in Q1 2025.
- Legal Proceedings: Review the status of the NCM bankruptcy appeal and the class action lawsuits regarding labor and product labeling.
- Liquidity Position: Confirm that cash reserves ($699.4 million) remain sufficient to cover the upcoming debt maturity and ongoing capital commitments without additional financing.